- Brief Report
Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort
- Rebecca K. Leaf,
- Hetanshi Naik,
- Paul Y. Jiang,
- Sarina B. Elmariah,
- Pamela Hodges,
- Jennifer Mead,
- John Trinidad,
- Behnam Saberi,
- Benny Tran and
- Amy K. Dickey
- + 4 authors
Background: Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare disorders of heme biosynthesis characterized by severe cutaneous phototoxicity. Afamelanotide, an α-melanocyte-stimulating hormone analogue, is the only...